

2018 EUnetHTA Forum

25 May, Cologne

Lindner City Plaza, Magnusstrasse 20, 50672 Köln, Germany

START	END	PROGRAMME ITEM	INVITED SPEAKERS
8.30	9.00	<i>Coffee and registration</i>	
9.00	9.20	Welcome and opening remarks	IQWiG, EC, and EUnetHTA
9.20	11.00	Session 1: Relevance, quality, and timeliness as drivers for uptake of EUnetHTA's work	
9.20	10.15	Completed, on-going, and planned updates to the Work Package (WP) 4 (Joint Production) procedure for both Other Technologies and Pharmaceuticals will be discussed. This update will focus on how WP4, WP6 (Quality Management), and WP7 (Implementation) have cooperated to address the important issues of relevance, quality, and timeliness through updates to the EUnetHTA procedures, templates, and via SOP development.	<ul style="list-style-type: none"> • WP4 Co-Lead Other Technologies • WP4 Co-Lead Pharmaceuticals • WP6 Lead Partner • WP7 Lead Partner
10.15	10.45	Q&A	
10.45	11.15	<i>Coffee break</i>	
11.15	12.45	Session 2: How can EUnetHTA predict and assist European health systems prepare for potentially disruptive innovation?	
11.15	12.15	A multi-stakeholder panel will discuss the opportunity for EUnetHTA's work to assist in identifying and assessing potentially disruptive and innovative technologies. Aspects addressed will reflect EUnetHTA's current thinking on topic selection, as well as collaboration in the horizon scanning space between regulators, EUnetHTA, and payers. Panellists will reflect on how the opportunities and challenges presented by these new technologies can be best managed. An open Q&A session will follow the panel.	<ul style="list-style-type: none"> • WP4 Lead Partner • WP5 Lead Partner • EMA representative • Payer representative • Medtech industry representative
12.15	12.45	Q&A	
12.45	14.00	<i>Lunch</i>	



European Network for Health Technology Assessment

14.00	15.30	Session 3: Taking lifecycle approach to EUnetHTA's work: Current and future collaboration between Early Dialogues and Relative Effectiveness Assessments	
14.00	14.45	Representatives from WP4 and WP5 will provide short presentations focused on harnessing the potential of cross-WP collaboration. More specifically, by means of EUnetHTA's activities in Early Dialogues, through the incorporation of learnings from joint Relative Effectiveness Assessments (REA), and via discussions on additional evidence generation needs, EUnetHTA has the tools in place to think about technologies along the lifecycle continuum. The advantages of such a lifecycle approach will be discussed and followed by an open Questions & Answer (Q&A) session.	<ul style="list-style-type: none"> • WP4 Lead Partner • WP4 Co-Lead Partners (Other Technologies and Pharmaceuticals) • WP5
14.45	15.15	Q&A	
15.15	15.45	<i>Coffee Break</i>	
15.45	17.20	Session 4: Start, Stop, Stay, Shift – How should EUnetHTA respond to the dynamic landscape of EU cooperation on HTA?	
15.45	16.50	EUnetHTA is nearing the halfway point of Joint Action 3 (JA3). In light of this milestone and coupled with the European Commission's recent proposal regarding collaboration on HTA, should EUnetHTA consider changes to or a re-focus of planned activities for the remainder of JA3 – or should it stay the course? A multi-stakeholder panel will reflect on this question. An open Q&A session will follow the panel.	<ul style="list-style-type: none"> • Patient representative • Consumer representative • Health care provider representative • Pharmaceutical industry representative • European Commission representative • EUnetHTA representative
16.50	17.20	Q&A	
17.20	17.30	Closing remarks	EUnetHTA

